Effect of Fentanyl on Main Opioid Receptor (OPRM1) on Human Granulosa Cells.
NCT ID: NCT03248076
Last Updated: 2017-12-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
30 participants
OBSERVATIONAL
2017-04-01
2018-10-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This study aims to investigate if a single exposure to opioids is enough to produce activation of stress mechanism during oocyte retrieval.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This study aims to investigate if a single exposure to opioids is enough to produce activation of stress mechanism during ultrasound-guided oocyte retrieval. It will be measured the level of cortisone before and 15min after iv administration of fentanyl on blood and on oocyte fluid.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Fentanyl citrate
Baseline blood sample and oocyte fluid will be collected under propofol anesthesia. Fifteen minutes after administration of 1γ/kgfentanyl, it will be collected again blood sample and oocyte fluid. Cortisone and fentanyl level will be measured in all samples.
Fentanyl Citrate
1γ/Kg fentanyl
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Fentanyl Citrate
1γ/Kg fentanyl
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* hepatic failure, hepatitis,
* drug abuse
* receiving b blockers
* receiving b agonists (even bronchodilators)
18 Years
32 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Papanikolaou Evaggelos
UNKNOWN
Naidecki Robert
UNKNOWN
Pakaki Fay
UNKNOWN
Raikos Nikolaos
UNKNOWN
George Papanicolaou Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Asouhidou Irene
Assisting Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Irene Asouhidou, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Assisting Nature
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Section of Anatomy, Aristotle University of Thessaloniki
Thessaloniki, , Greece
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Irene Asouhidou, MD, PhD
Role: primary
Evaggelos Papanikolaou, MD, PhD
Role: backup
References
Explore related publications, articles, or registry entries linked to this study.
Bottcher B, Seeber B, Leyendecker G, Wildt L. Impact of the opioid system on the reproductive axis. Fertil Steril. 2017 Aug;108(2):207-213. doi: 10.1016/j.fertnstert.2017.06.009. Epub 2017 Jun 29.
Lunger F, Vehmas AP, Furnrohr BG, Sopper S, Wildt L, Seeber B. Opiate receptor blockade on human granulosa cells inhibits VEGF release. Reprod Biomed Online. 2016 Mar;32(3):316-22. doi: 10.1016/j.rbmo.2015.12.006. Epub 2016 Jan 6.
Kouvaras E, Asprodini EK, Asouchidou I, Vasilaki A, Kilindris T, Michaloudis D, Koukoutianou I, Papatheodoropoulos C, Kostopoulos G. Fentanyl treatment reduces GABAergic inhibition in the CA1 area of the hippocampus 24 h after acute exposure to the drug. Neuropharmacology. 2008 Dec;55(7):1172-82. doi: 10.1016/j.neuropharm.2008.07.025. Epub 2008 Jul 26.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Opioids-OPU
Identifier Type: -
Identifier Source: org_study_id